About this medicine

Some antipsychotics produce stiffness or tremor resembling parkinsonism. Trihexyphenidyl may reduce these symptoms; the original medicine and the type of movement problem still need review.

Benzhexol is an older name for trihexyphenidyl. Stiffness, spasms, restlessness and delayed involuntary movements are different clinical problems; recognising the movement pattern matters before choosing treatment. This medicine does not treat psychosis itself.

What is this medicine used for?

The syrup is licensed for parkinsonism and drug-induced extrapyramidal syndrome. It is not recommended for tardive dyskinesia, which it can provoke or worsen.

The separately checked Ennogen 2 mg and 5 mg tablets are licensed for parkinsonism and for prevention and control of drug-induced extrapyramidal symptoms, excluding tardive dyskinesia. Their SmPC recommends keeping treatment for drug-induced symptoms to the minimum duration needed after symptoms settle, with prescriber review of the causative medicine.

A product licence does not by itself establish a preferred NHS treatment, current pharmacy stock or a specialist childhood regimen. The tablet and syrup sources each state that use in children is not recommended.

Which warning signs need help?

Severe allergy, a painful eye with altered vision, inability to pass urine, marked confusion or suspected overdose needs urgent assessment. Overdose can cause high temperature and serious neurological or cardiac effects; do not wait for symptoms after a suspected overdose.

Severe constipation, abdominal swelling or vomiting needs prompt assessment, especially with clozapine or other antimuscarinic medicines. Review newly emerging involuntary movements: trihexyphenidyl can worsen tardive dyskinesia.

The tablet information warns of misuse because euphoria and hallucinations can occur. New agitation, delusions, pronounced memory problems or unusual behaviour needs prompt clinical review. Severe reactions or suspected overdose require urgent local medical help; the correct emergency service depends on the person's actual country.

How do I take it safely?

The Rosemont syrup contains 1 mg/mL. Its patient leaflet describes an initial 2 mg daily and gradual clinician-led adjustment up to 20 mg daily. This is the adult syrup's reference schedule, not a dosing instruction for childhood dystonia or a tablet.

The independently checked Ennogen tablet SmPCs start adult treatment at 1 mg on day 1 and 2 mg on day 2, with further small increases at intervals of three to five days. They describe usual totals of 6–10 mg daily for parkinsonism and 5–15 mg daily for drug-induced symptoms, although some people need less and older people may be especially sensitive.

Doses are divided during the day. These are product reference ranges, not instructions to start or adjust treatment without a prescriber.

The tablet SmPC allows timing around meals to be adjusted for dry mouth or nausea. Although the tablets have a break line, the checked documents do not state that it produces equal-dose halves. Do not assume that splitting, crushing or substituting syrup is suitable without checking the dispensed product with a pharmacist.

Measure the prescribed syrup with an appropriate medicine measure. Keep the syrup below 25°C and do not refrigerate or freeze it. Keep tablets in their original blister or the tightly closed container specified by the leaflet. Different preparations have different excipients and storage instructions.

What side effects should I know about?

Dry mouth, constipation, nausea, blurred vision and dizziness are recognised in the current product information. Confusion, memory difficulty and hallucinations also matter, especially in older people. Avoid driving when vision or alertness is impaired.

The tablet leaflet also lists nervousness and disturbances of vision or heart rate. Persistent dry mouth, constipation or troublesome symptoms merit review, rather than simply accepting them as unavoidable. New confusion, delusions or hallucinations can be medicine effects, particularly in older adults.

Who needs extra care with this medicine?

Glaucoma, urinary or bowel obstruction, prostate problems and myasthenia gravis need particular care. Older adults are more susceptible to confusion and hallucinations.

Allergy to trihexyphenidyl or a product ingredient is a contraindication. The tablet SmPC treats hypertension and heart, liver or kidney disease as conditions needing caution, rather than declaring them all absolute contraindications. Myasthenia gravis requires avoidance or great caution.

The tablets contain lactose and have specific restrictions for rare galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. This is separate from the syrup's sucrose and propylene glycol precautions; changing formulation does not erase excipient risks.

Can it affect my other medicines?

Clozapine, sedating antihistamines, tricyclic antidepressants and other antimuscarinics add adverse effects. Levodopa and medicines affecting gut movement may also interact.

The tablet SmPC identifies additive antimuscarinic effects with medicines including clozapine, phenothiazines, antihistamines, amantadine, disopyramide and nefopam. Tricyclic antidepressants and monoamine oxidase inhibitors can also intensify unwanted effects.

Trihexyphenidyl can oppose the gut-movement effects of metoclopramide or domperidone and may reduce levodopa absorption. A clinician or pharmacist should review the whole medicine list, including non-prescription products; this article is not an interaction checker or an instruction to stop another medicine.

What check-ups will I need?

Review the movement problem and continuing benefit alongside cognition, bowel and bladder function, vision and heart-related symptoms. People with cardiac, liver or kidney disease need closer observation; older people are particularly vulnerable to confusion and hallucinations.

Distinguish relief of parkinsonian stiffness from new involuntary movements, and reassess adverse effects as the original medicine changes. The current tablet and syrup product information supports this review. The older local titration leaflet is not used as current dosing or monitoring authority.

The practical question is whether improved movement and everyday functioning outweigh unwanted effects and whether the medicine remains necessary. The checked SmPCs do not provide a universal scheduled blood-test programme; condition-specific monitoring should follow the treating team's assessment.

What about pregnancy, breastfeeding and age?

The Rosemont syrup does not recommend children. Its SmPC reserves pregnancy use for clear necessity and states that it should not be used during breastfeeding. Off-label specialist treatment is a separate decision, not a change to these product instructions.

The syrup contains sucrose and propylene glycol. Sucrose matters in diabetes and certain inherited sugar-intolerance disorders; the product warns against use with hereditary fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Kidney or liver impairment can also require extra attention to propylene glycol.

The tablet SmPCs independently restrict pregnancy use to clear necessity, say not to use during breastfeeding, and do not recommend use in children. Adults over 65 are particularly susceptible to confusion and hallucinations and may need smaller amounts. Specialist off-label decisions require their own evidence and monitoring plan.

What if I miss a dose or want to stop?

Do not double a forgotten dose or abruptly stop regular treatment. The prescriber plans gradual reduction because movement symptoms may worsen after sudden cessation.

The tablet leaflet advises taking a forgotten dose when remembered unless the next is nearly due, without doubling. Planned withdrawal is gradual under the prescriber's instructions. Urgent adverse effects or overdose still require immediate advice rather than waiting for a routine taper discussion.

How does it work?

Trihexyphenidyl changes some of the messages involved in controlling movement. It reduces the effects of acetylcholine, a chemical messenger, and can ease certain symptoms such as stiffness and shaking. It does not restore lost nerve cells or work for every type of movement problem.

How Brain Cells Communicate

Movement depends on groups of brain cells passing messages to one another. Two of the chemical messengers involved are acetylcholine and dopamine.

Cells respond to these messengers through receptors, proteins that receive particular signals. Muscarinic receptors are one group of receptors for acetylcholine. Changes in dopamine signaling can also affect how these connected movement systems work.

What is known: Several chemical messengers work together to control movement.

What remains uncertain: A movement problem cannot be understood simply as too much or too little of one chemical.

Acetylcholine: Muscarinic receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Acetylcholine: A messenger can change signaling through its receptor. Muscarinic receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Acetylcholine

    A messenger can change signaling through its receptor.

  2. Muscarinic receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Acetylcholine can activate muscarinic receptor and change signaling in the cell.

Several chemical messengers work together to control movement. Simplified illustration of the process; individual responses vary.
About this illustration

Acetylcholine; Muscarinic sites; Cell responses. A movement problem cannot be understood simply as too much or too little of one chemical.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Trihexyphenidyl blocks muscarinic receptors and reduces some of acetylcholine’s effects. This is called an antimuscarinic action. It can help some symptoms of parkinsonism, a pattern of slowed movement, stiffness or shaking. Parkinsonism can occur in Parkinson’s disease or develop as a side effect of medicines that block dopamine signals.

What is known: The medicine changes the response to acetylcholine without replacing dopamine.

What remains uncertain: It does not help tardive dyskinesia, repeated movements a person cannot control that may follow longer-term use of dopamine-blocking medicines, and can make it worse.

Trihexyphenidyl: Muscarinic receptor

A receptor with natural messenger and a separate terracotta medicine symbol above the membrane; intracellular proteins illustrate the downstream signaling context. Acetylcholine: A messenger can change signaling through its receptor. Muscarinic receptor: This receptor symbol identifies a function, not a molecular structure. Trihexyphenidyl: activation opposed: The crossbar marks opposition to receptor activation, not permanent closure.
  1. Acetylcholine

    A messenger can change signaling through its receptor.

  2. Muscarinic receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Trihexyphenidyl: activation opposed

    The crossbar marks opposition to receptor activation, not permanent closure.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Trihexyphenidyl blocks muscarinic acetylcholine receptors. This is not dopamine replacement or restoration of lost dopamine-producing cells.

The medicine changes the response to acetylcholine without replacing dopamine. Simplified illustration of the process; individual responses vary.
About this illustration

Medication; Muscarinic blockade; Changed signaling. It does not help tardive dyskinesia, repeated movements a person cannot control that may follow longer-term use of dopamine-blocking medicines, and can make it worse.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

The medicine’s effects extend beyond the brain’s movement systems. Acetylcholine also helps with memory, saliva production, sweating, bowel movement and bladder emptying.

Reducing those signals can cause unwanted effects in these areas. Central effects are effects in the brain and spinal cord; peripheral effects happen elsewhere in the body. Both can matter with trihexyphenidyl.

What is known: Its action at muscarinic receptors helps explain both symptom relief and several side effects.

What remains uncertain: Which effects are most noticeable varies with the person and their other medicines.

How the process works

  1. Brain and body
  2. Receptor blockade
  3. Benefit and harm
Its action at muscarinic receptors helps explain both symptom relief and several side effects. Simplified illustration of the process; individual responses vary.
About this illustration

Brain and body; Receptor blockade; Benefit and harm. Which effects are most noticeable varies with the person and their other medicines.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Drying and bowel-slowing effects can accumulate when other anticholinergic medicines are taken. New forgetfulness, confusion or hallucinations may be adverse effects rather than worsening psychiatric illness.

Reduced sweating can make overheating more likely. Blurred vision, dizziness and mental clouding can affect driving or operating machinery. These effects may be more troublesome with higher exposure or other antimuscarinic medicines; they should be reviewed alongside any improvement in stiffness or tremor.

How does my body process it?

The checked SmPC reports good gastrointestinal absorption but provides little detailed pharmacokinetic information. This profile therefore does not invent a precise half-life or enzyme pathway.

The tablet SmPC similarly describes good absorption from the gut and rapid disappearance from plasma and tissues, without accumulation at conventional doses. It does not provide enough quantitative information to construct a reliable personalised elimination timetable. Changes in preparation therefore still need a clear prescribed dose and administration plan.

How do treatment options differ?

Tardive dyskinesia and drug-induced parkinsonism require different approaches. A medicine helping one can worsen the other, so identifying the movement pattern comes before choosing an adjunct.

Different antimuscarinic medicines and formulations are not interchangeable milligram for milligram. A prescriber may instead review the medicine causing the symptoms. That decision depends on the movement disorder and the original treatment's benefits; it cannot be made from a class label alone.

A closer look at the science

The molecule is a tertiary-amine antimuscarinic with smooth-muscle antispasmodic effects. It is not a dopamine replacement and does not treat psychosis itself.

The checked tablets contain trihexyphenidyl hydrochloride. The UK SmPC describes a selective anticholinergic action and direct antispasmodic effects on smooth muscle, rather than a molecular mechanism that predicts an individual's response. The shared chemical illustration describes the ingredient; it does not certify a particular product, dose or indication.

Trihexyphenidyl hydrochloride is a salt. The neutral parent is C20H31NO; HCl identifies the additional salt component. The drawing describes atom connections, not a receptor-bound pose.

Chemical formula: C20H31NO · HCl

The neutral-parent drawing omits hydrochloride. Neither the chemical formula nor an illustration identifies a finished tablet or syrup, establishes dose equivalence, or determines which movement disorder should be treated.

PubChem trihexyphenidyl neutral-parent chemical structure; hydrochloride omitted.
PubChem CID 5572: neutral trihexyphenidyl connectivity. Hydrochloride is specified separately; lines show bonds, corners generally represent carbon, and many hydrogen atoms are omitted.

Neutral parent only; hydrochloride salt partner specified separately. No receptor-bound conformation is implied.

How was this medicine developed?

This is an established antimuscarinic, but long use does not remove safety concerns. The checked syrup's authorisation dates to 2011; its SmPC was revised in March 2023.

A King's College Hospital local leaflet, issued in December 2022 with review due December 2025, provides historical service context only. It is not treated here as a current national titration protocol or as verification of today's tablet products.

The current checked Ennogen tablet texts are dated 24 July 2026 for 2 mg (PL 55612/0143) and 13 July 2026 for 5 mg (PL 55612/0144). The 2 mg document repeats its authorisation number in the authorisation-date field, so no date has been inferred from that field. A hosted product document confirms its particulars, not live pharmacy stock.

Sources and References

  1. Trihexyphenidyl hydrochloride 5 mg/5 mL syrup: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Trihexyphenidyl syrup: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  3. Trihexyphenidyl titration: patient information

    Scope: England, local spasticity service.

  4. Trihexyphenidyl hydrochloride: abbreviated prescribing information

    Scope: United Kingdom.

  5. Crescent Pharma product portfolio: trihexyphenidyl 2 mg and 5 mg tablets

    Scope: United Kingdom.

  6. Trihexyphenidyl 2 mg Tablets: UK Summary of Product Characteristics

    Scope: United Kingdom.

  7. Trihexyphenidyl 5 mg Tablets: UK Summary of Product Characteristics

    Scope: United Kingdom.

  8. Trihexyphenidyl 2 mg and 5 mg Tablets: patient information leaflet

    Scope: United Kingdom.

  9. Trihexyphenidyl hydrochloride tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology; Indications; Precautions; Adverse Reactions..

  10. Trihexyphenidyl: patient information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?; Side effects..

  11. An evidence-based update on anticholinergic use for drug-induced movement disorders

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  12. Trihexyphenidyl: supplementary ingredient safety labeling (Bionpharma products have ended marketing)

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  13. Trihexyphenidyl: PubChem CID 5572

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  14. Tardive dyskinesia: MedlinePlus Medical Encyclopedia
  15. NIMH: Mental Health Medications
  16. NIMH: Understanding psychosis
  17. Schizophrenia
  18. Cultural Formulation in Diagnosis and Cultural Concepts of Distress - Improving Cultural Competence - NCBI Bookshelf

Shared scientific background. US product pharmacology and international chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top